Drug in OUtMATCH Clinical Trial FDA-Approved for the Reduction of Allergic Reactions from Accidental Food Exposures
February 29, 2024
Stage one results from the OUtMATCH clinical trial, published in the New England Journal of Medicine, show that a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as age one could consume without an allergic reaction. Edwin Kim,...